Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |
Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Neuroscience · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology (Index, Outline)
Phendimetrazine chemical structure
| CAS number |
| ATC code |
| PubChem |
| DrugBank |
|Bioavailability||Peak plasma levels occur within 1 to 3 hours. Absorption is usually complete by 4 to 6 hours|
|Elimination half-life||19-24 hours|
|Pregnancy category||C (US)|
|Legal status||C-III (US)|
|Routes of administration||Oral|
Phendimetrazine (Bontril®) is a weight loss medication. Phendimetrazine is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances. In the United States, phendimetrazine is a Schedule III controlled substance under the Uniform Controlled Substances Act of 1970.
Phendimetrazine is used clinically in the form of phendimetrazine tartrate.
Approximately 30% of a given dose of phendimetrazine is metabolized into phenmetrazine, which may account for part of its anorectic effect, and probably also influences abuse potential; individuals who metabolise a greater proportion of phendimetrazine into phenmetrazine are more likely to develop problems with dependence and addiction.
According to the "List of psychotropic substances under international control," phendimetrazine is a Schedule IV controlled substance.[How to reference and link to summary or text]
|This page uses Creative Commons Licensed content from Wikipedia (view authors).|